SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Muñoz J. L.)
 

Search: WFRF:(Muñoz J. L.) > (2005-2009) > The Impact of Quadr...

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years

Brown, Darron R. (author)
Kjaer, Susanne K. (author)
Sigurdsson, Kristjan (author)
show more...
Iversen, Ole-Erik (author)
Hernandez-Avila, Mauricio (author)
Wheeler, Cosette M. (author)
Perez, Gonzalo (author)
Koutsky, Laura A. (author)
Tay, Eng Hseon (author)
Garcia, Patricia (author)
Ault, Kevin A. (author)
Garland, Suzanne M. (author)
Leodolter, Sepp (author)
Olsson, Sven-Eric (author)
Karolinska Institutet
Tang, Grace W. K. (author)
Ferris, Daron G. (author)
Paavonen, Jorma (author)
Steben, Marc (author)
Bosch, F. Xavier (author)
Dillner, Joakim (author)
Karolinska Institutet,Lund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups
Joura, Elmar A. (author)
Kurman, Robert J. (author)
Majewski, Slawomir (author)
Munoz, Nubia (author)
Myers, Evan R. (author)
Villa, Luisa L. (author)
Taddeo, Frank J. (author)
Roberts, Christine (author)
Tadesse, Amha (author)
Bryan, Janine (author)
Lupinacci, Lisa C. (author)
Giacoletti, Katherine E. D. (author)
Sings, Heather L. (author)
James, Margaret (author)
Hesley, Teresa M. (author)
Barra, Eliav (author)
show less...
 (creator_code:org_t)
Oxford University Press (OUP), 2009
2009
English.
In: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 926-935
  • Conference paper (peer-reviewed)
Abstract Subject headings
Close  
  • Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Publication and Content Type

kon (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view